SCHEMBL16459165

SCHEMBL16459165

CC1(CO)COC(c2ccc(-c3ccccc3)cc2)=N1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
LPL P06858 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
HRH3 Q9Y5N1 3/20 0.36
CYP2D6 P10635 1/20 0.36
MMP9 P14780 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CHRNA1 P02708 1/20 0.35
CHRNG P07510 1/20 0.35
CHRNB1 P11230 1/20 0.35
CHRNB2 P17787 1/20 0.35
SLC6A2 P23975 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
CHRND Q07001 1/20 0.35
HTR1A P08908 1/20 0.35
HTR2B P41595 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12471989 0.97 LMNA (0.66) LMNAHRH3CYP2D6KDM4EMAPT
SCHEMBL16459758 0.86 LMNA (0.47) LMNAHRH3CYP2D6MMP9KDM4E
SCHEMBL16459397 0.84 LMNA (0.46) LMNAHRH3CYP2D6MMP9KDM4E
SCHEMBL16460055 0.84 LMNA (0.46) LMNAHRH3CYP2D6KDM4EMAPT
SCHEMBL16459040 0.84 LMNA (0.46) LMNAHRH3CYP2D6MMP9KDM4E
SCHEMBL23480876 0.84 LMNA (0.46) LMNAHRH3CYP2D6KDM4EMAPT
SCHEMBL16460189 0.84 LMNA (0.50) LMNALPLLIPGHRH3CYP2D6
SCHEMBL16459946 0.82 LMNA (0.46) LMNALPLLIPGKDM4ECHRNA1
SCHEMBL16459020 0.82 MEN1 (0.45) LMNAHRH3KDM4EMAPTESR2
SCHEMBL16459638 0.81 LMNA (0.47) LMNAHRH3KDM4ECHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969585-B2 Method for producing optically active compound or salt thereof NAGASAKI UNIVERSITY (JP) 2015-03-03 US disclosed
US-8969585-B2 Method for producing optically active compound or salt thereof NAGASAKI UNIVERSITY (JP) 2015-03-03 US disclosed
US-8969585-B2 Method for producing optically active compound or salt thereof NAGASAKI UNIVERSITY (JP) 2015-03-03 US disclosed
US-20140012010-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF NAGASAKI UNIVERSITY (JP) 2014-01-09 US disclosed
US-20140012010-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF NAGASAKI UNIVERSITY (JP) 2014-01-09 US disclosed
US-20140012010-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF NAGASAKI UNIVERSITY (JP) 2014-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140012010-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND OR SALT THEREOF MINK1, MELK, MRPL21 LMNA 1949/4885LPL 1112/4885LIPG 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.